. Author manuscript; available in PMC: 2012 Aug 6.

Published in final edited form as: Cancer. 2010 Oct 19;117(6):1210–1219. doi: 10.1002/cncr.25568

Table 4.

AUC for diagnosis of prostate cancer based on total PSA at baseline, calculated separately for men diagnosed at various intervals from baseline. All associations between PSA and outcome were significant at p<0.0005.

Time to diagnosis	Any cancer		Palpable cancer		Advanced cancer

	Cases	AUC (95% CI)	Cases	AUC (95% CI)	Cases	AUC (95% CI)
≤15 years	107	0.842 (0.790, 0.891)	69	0.848 (0.783, 0.907)	47	0.859 (0.778, 0.929)
16–19 years	263	0.724 (0.688, 0.760)	162	0.753 (0.706, 0.796)	82	0.745 (0.681, 0.804)
20–24 years	607	0.725 (0.703, 0.749)	317	0.727 (0.694, 0.758)	147	0.756 (0.708, 0.800)
≥25 years	335	0.670 (0.637, 0.702)	170	0.644 (0.608, 0.700)	86	0.686 (0.628, 0.768)